gbmn GEORGIAN BIOMEDICAL NEWS

PROF. MARINA JANELIDZE

EDUCATION

- 1969-75 Tbilisi State Medical Institute;
- 1975-77 Sarajishvili Institute of Neurology, Postgraduate clinical Training;
- 1977-80 Sarajishvili Institute of Neurology and Institute of Neurology of Medical Academy of the USSR, Postgraduate clinical researcher.

WORKING EXPERIENCE

- 2006 till today - Professor, Head of Department of Clinical Neurology, Tbilisi State Medical University, S. Khechinashvili University Hospital;
- 2000 till 2006 - Professor, Head of Chair of Neurology of Tbilisi State Medical Academy;
- 1999-2006 - Sarajishvili Institute of Neurology, Head of Neurological Clinic;
- 1996-2005 - Professor of Tbilisi State University, department of neurology and neurosurgery;
- 1992-1999 - Sarajishvili Institute of Neurology deputy director;
- 1986-1992 - Sarajishvili Institute of Neurology, senior scientific researcher;
- 1980-1986 - Sarajishvili Institute of Neurology, junior scientific researcher.

SOCIAL ACTIVITY

- 2009 - Cofounder of NGO Neuroforum;
- 2016 - Cofounder and Secretary General of NGO Georgian Union of Neurologists.

IMPORTANT SCIENTIFIC WORKS

- 1981 - dissertation for the degree of candidate of medical science “Peculiarities of T and B lymphocytes in secondary generalized epileptic seizures and temporal epilepsy”;
- 1995 - dissertation for the degree of doctor of medical science “Neurological aspects of primary dementias“;
- 2002-2011 - Malcolm Carpenter “Core Text of Neuroanatomy” - translation from English to Georgian two editions;
- 2009-2013 - Clinical Neurology - textbook for students and residents - two editions;
- Z Katsarava, A. Dzagnidze, M. Kukava, E. Mirvelashvili, M. Djibuti, M. Janelidze R. Jensen, I. Stovner, Tj Steiner Prevalence of Cluster Headache in the Republic of Georgia: Results of a Population Based Study and Methodological Considerations Cephalalgia 2009 Sep;29(9):949-52. doi: 10.1111/j.1468-2982.2008.01836. x.

- Z. Katsarava, A. Dzagnidze, M.KUkava, E. mirvelashvili, M.Djibuti, M. Janelidze, R. Jensen, L.J Stovner, T.J Steiner Primary headache disorders in the Republic of Georgia: prevalence and risk factors Neurology. 2009 Nov 24;73(21):1796-803
- Jan Rusz, Marika Megrelishvili, Cecilia Bonnet, Michael Okujava,, Madona Sexniashvili Marina Janelidze A distinct variant of mixed dysarthria reflects parkinsonism and dystonia due to ephedrone abuse Journal of Neural Transmission 2014 121: 655-664
- Cecilia Bonnet, Jan Rusz, Marika Megrelishvili, Tomas Sieger Olga Matouskova, Michael Okujava, Marina Janelidze Hana Brozova et oth. Eye Movements in Ephedrone-induced Parkinsonism PLOS one 2014 vol.9 Issue 8 e104784
- Marina Janelidze, MD, PhD, Nina Mikeladze, MD, Nazibrola Bochorishvili, MD, Ann Dzagnidze MD, PhD, Mariam Kapianidze, MD, Nino Mikava, MD, PhD, Irene Khatiashvili, MD, PhD3, Darejan Kakhiani, PhD, Ekaterina Mirvelashvili, MD, PhD, Nino Shiukashvili, MD, and Zurab Nadareishvili, MD, PhD Validity of the Georgian Montreal Cognitive Assessment for the Screening of Mild Cognitive Impairment and Dementia; American Journal of Alzheimer's Disease & Other Dementias; 2017, Vol. 32(1) 36-40
- Marina Janelidze, MD, PhD, Nina Mikeladze, MD, Nazibrola Bochorishvili, MD, Ann Dzagnidze, MD, PhD, Mariam Kapianidze, MD, Nino Mikava, MD, PhD, Irene Khatiashvili, MD, PhD, Ekaterina Mirvelashvili, MD, PhD, Nino Shiukashvili, MD, John Lynch, DO, MPH, and Zurab Nadareishvili, MD, PhD Mild Cognitive Impairment in Republic of Georgia Gerontology & Geriatric Medicine Volume 4: 1–10 The Author(s) 2018
- Botchorishvili N, Shiukashvili N, Mikeladze N, Dzagnidze A, Mikava N, Tighashvili M, Janelidze M. Validity and reliability of the Georgian-language brief international cognitive assessment for multiple sclerosis (BICAMS). BMC Neurol. 2021 Jun 9;21(1):218. doi: 10.1186/s12883-021-02249-x. PMID: 34107913; PMCID: PMC8188683.
- Botchorishvili N, Shiukashvili N, Mikeladze N, Dzagnidze A, Mikava N, Tighashvili M, Janelidze M. Screening of Cognitive Impairment in Patients with Multiple Sclerosis: A Cross-Sectional Study in Georgia. Neurol Res Int. 2021 May 27; 2021:5591078. doi: 10.1155/2021/5591078. PMID: 34136283; PMCID: PMC8178012.

PARTICIPATION IN CLINICAL TRIAL AS A PI

- Protocol number: 205MS303 - A phase 1. A multicenter, Open-Label, Extension Study to Evaluate the Long –term Safety and Efficacy of BIIB019, Daclizumab High Yield Process (DAC HYP), Mono-therapy in Subjects with Multiple Sclerosis Who Have Completed Study 205MS301;
- Protocol number: RPC01-201 - Phase 2. Multicenter, randomized, Double-blind, Double-Dummy, Active-controlled, Parallel, group-study to evaluate the efficacy and safety of RPC1063 administered orally to relapsing multiple sclerosis patients;
- Protocol number: RPC01-301 - Phase 3. Multicenter, randomized, Double-blind, Double-Dummy, Active-controlled, Parallel, group-study to evaluate the efficacy and safety of RPC1063 administered orally to relapsing multiple sclerosis patients;
- Protocol number: LAQ-MS-305 (concerto) - Study title: A multinational, multicenter, randomized, double-blind, parallel group, placebo-controlled study followed by an active treatment period, to evaluate the efficacy, safety and tolerability of two doses of oral administration of laquinimod (0.6mg/day or 1.2 mg/day) in subjects with relapsing remitting multiple sclerosis (RRMS);
- Protocol Amendment No: 5 - A phase III, randomized, double-blind, placebo-controlled, multicenter clinical trial of oral cladribine in subjects with a first clinical event at high risk of converting to MS;

- Protocol ID: 105MS301 - A multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of PEGylated interferon Beta-1a (BIIB017) in subjects with Relapsing Multiply Sclerosis;
- Stroke in Young Fabry Patients (sifap1): Frequency of Fabry Disease in an Unselected Group of Young Stroke Patients: An International, Multi-center Prevalence Study
- ClinicalTrials.gov Identifier: NCT00414583;
- Protocol AC -058 B301 Optimum - Multicenter, randomized, double blind parallel-group, active-controlled, superiority study to compare the efficacy and safety of ponesimod to teriflunomide in subjects with relapsing multiple sclerosis;
- Protocol N: SA-309JG - A multicenter, Randomized, Double-Blind, Placebo-Controlled, phase 3 study to evaluate the efficacy and safety of SA237 as mono-therapy in patients with neuro-myelitis Optica (NMP) and neuro-myelitis Optica spectrum disorder (NMOSD);
- Protocol N: 1014802-204 Phase 2, An uncontrolled, Open-label extension study to evaluate the long-therm safety, tolerability and maintenance of effect of BIIB074 in subject with neuropathic pain from lumbosacral radiculopathy;
- Protocol N: ALD403-CLIN-006 - a parallel group double-blind randomized placebo-controlled trial to evaluate the efficacy and safety pf ALD403 administration intravenously in patients with frequent episodic migraines;
- Protocol N: ALD403-CLIN-011 - a parallel group double-blind randomized placebo-controlled trial to evaluate the efficacy and safety pf ALD403 administration intravenously in patients with chronic migraines;
- Protocol MG0003 - A phase 3, randomized, double-blind, placebo-controlled study
- evaluating efficacy and safety of rozanolixizumab in adult patients with generalized myasthenia gravis;
- Protocol MG0007 - phase 3 An open Label exxension study to evaluate rozanolixizumab in study participate with generalized myasthenia gravis;
- Protocol N ARGX- 113-1902- Adhere- A phase 2 trial to investigate the Efficacy, Safety and Tolerability of Efgartigimod in Adult Patient with Chronic Inflammatory Demyelinating Polyneuropathy;
- Protocol N ARGX- 113-1902- Adhere- Open label extension of the ARGX- 113-1902- to investigate the Efficacy, Safety and Tolerability of Efgartigimod in Adult Patient with Chronic Inflammatory Demyelinating Polyneuropathy.

LANGUAGE SKILLS

- Georgian – native;
- English – fluent;
- French – read and translate with dictionary;
- Russian – fluent.